Keros Therapeutics, Inc.

NASDAQ:KROS

Biotechnology

Healthcare
$12.00 +1.20%

+$0.13 today

Market cap
$235.49M
Beta
0.96
P/E (TTM)
-4.6
EPS (TTM)
-$2.29
52W Low $9.69High $22.55

Volume 0.55M

Average 0.36M

KROS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Keros Therapeutics, Inc.NASDAQ: KROS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns negative

Q1 FY2026 EBITDA was -$23.31M, compared with $158.84M a year earlier. Trailing-twelve-month EBITDA was -$88.74M.

Context

  • EBITDA amounted to 38.3% of revenue in FY2025, down 5196.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$154.14M (-265.0%) for the fiscal year ending Dec 2026, a slowdown from the +150.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.31M+5.2% QoQ
Last fiscal yearDec 2025
$93.41M+150.3% YoY
LTMMar 2026
-$88.74M-376.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-114.7%+17.5%+132.2 pp
1 year+150.3%-265.0%-415.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
93.41M USD
Year-over-year change
+150.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How KROS compares with its peers on the latest reported figures

  • KROS's LTM Mar 2026 EBITDA of -$88.74M is the 5th highest of the 10 companies compared; the peer median is -$106.84M.
  • Its year-over-year change of -376.4% is the lowest of 10, against a peer median of -32.3%.
  • EBITDA amounts to 267.4% of revenue for KROS, versus a peer median of 211.7%.
KROS Competitors Peer median
EBITDA for KROS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M +170.9%—43.8%
NAGENiagen Bioscience IncLTM Mar 2026$21.4M +33.4%—16.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$42.27M -2.3%——
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$57.67M -232.5%—162.2%
KROSKeros Therapeutics, Inc.LTM Mar 2026-$88.74M -376.4%—267.4%
ABSIAbsci CorporationLTM Mar 2026-$106.84M -14.3%—5818.9%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$184.67M -43.8%——
VSTMVerastem, Inc.LTM Mar 2026-$191.95M -32.3%—387.1%
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$245.81M -69.1%——
Peer median (excluding KROS) -$106.84M-32.3%—211.7%

Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.1M0151K3.55M244.06M
Cost of Revenue00001.51M
Gross Profit20.1M0151K3.55M242.55M
Gross Margin100.0%—100.0%100.0%99.4%
Research & Development55.14M87.27M135.26M173.63M129.64M
Selling, General & Admin21.33M27.53M34.83M40.75M46.85M
Operating Expenses76.47M114.79M170.09M214.38M171.93M
Depreciation & Amortization378K674K815K1.23M1.51M
EBITDA(56.35M)(104M)(152.18M)(185.82M)93.41M
EBITDA Margin-280.4%—-100779.5%-5234.5%38.3%
Operating Income(56.37M)(114.79M)(169.94M)(210.83M)70.62M
Operating Margin-280.5%—-112543.7%-5939.0%28.9%
Interest Income01K000
Interest Expense4K1K000
Other Income / Expenses(360K)10.11M16.95M23.78M21.27M
Income Before Tax(56.73M)(104.68M)(152.99M)(187.05M)91.9M
Pre-Tax Margin-282.3%—-101319.2%-5269.1%37.7%
Income Tax Expense2.01M00300K4.88M
Net Income(58.74M)(104.68M)(152.99M)(187.35M)87.01M
Net Margin-292.3%—-101319.2%-5277.5%35.7%
EPS (Basic)(2.52)(4.15)(5.20)(5.00)2.34
EPS (Diluted)(2.52)(4.15)(5.20)(5.00)2.30
Weighted Avg Shares23.33M25.24M29.45M37.44M37.22M
Weighted Avg Shares (Diluted)23.33M25.24M29.45M37.44M37.86M

Keros Therapeutics, Inc.

NASDAQ:KROS

Intrinsic Alpha fair value

Locked

Current Price

$12.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.